Biotech News
Related news
EDITEditas Medicine2026-10-14 13:00 EST
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
COGTCogent Biosciences2026-10-27 20:01 EST
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
CRBUCaribou2026-11-05 21:05 EST
Caribou Biosciences Reports Third Quarter 2026 Financial Results
REGNRegeneron Pharmaceuticals2026-11-02 21:05 EST
Regeneron Announces Investor Conference Presentations
NTLAIntellia2026-10-29 12:00 EST
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
CRBUCaribou2026-10-06 20:05 EST
Caribou Biosciences to Evaluate Strategic Alternatives
SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
SNDXSyndax Pharmaceuticals2026-11-04 14:00 EST
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
GERNGeron2026-11-03 13:00 EST
Geron Corporation to Participate in the Stifel 2026 Healthcare Conference
EXELExelixis2026-11-03 21:05 EST
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Caribou
Allogeneic Cell Therapy Caribou Biosciences develops off-the-shelf CAR-T cell therapies using its CRISPR genome-editing platform. Its candidates incorporate multiple edits intended to improve persistence, antitumor activity and compatibility with donor-derived cells. Vispa-cel Vispacabtagene regedleucel, or vispa-cel, is an allogeneic...
Recent company news
CRBUCaribou2026-11-05 21:05 EST
Caribou Biosciences Reports Third Quarter 2026 Financial Results
CRBUCaribou2026-11-04 14:00 EST
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
CRBUCaribou2026-10-06 20:05 EST
Caribou Biosciences to Evaluate Strategic Alternatives
CRBUCaribou2026-08-13 20:05 EST
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
CRBUCaribou2026-06-29 12:00 EST
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Stock data
- Close
- 0.41 USD
- Market cap
- 230.1M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States